The short version of Melanotan II fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Synthesis == The process used to create DBNPA is acid-catalyzed bromination of 3-cyanoacetamide. Polyethylene glycol is often used as the solvent due to its ability to dissolve both reactants and products effectively. Next, the bromination step is initiated by introducing bromine (Br2) or an alternative brominating agent, such as sodium bromide (NaBr) with an oxidant. DBNPA is formed as a result of an electrophilic bromination reaction at the α-carbon of 3-cyanoacetamide. Isolation and purification of DBNPA are carried out after bromination. The reaction mixture is neutralized, and the product is extracted and purified. The next step is drying, which yields DBNPA in its stable crystalline form. Usually, the reaction temperature is kept between 10 and 20 °C to minimize unintended side reactions. The concentration of bromine is carefully controlled, because an excess can lead to the formation of undesired byproducts that reduces the overall yield. The stability of DBNPA depends on the storage conditions. Due to its incompatibility with metals, DBNPA should be stored in non-metal containers. It must also be stored away from UV exposure, as this can degrade DBNPA.
The browning reactions that occur when meat is roasted or seared are complex and occur mostly by Maillard browning with contributions from other chemical reactions, including the breakdown of the tetrapyrrole rings of the muscle protein myoglobin. Maillard reactions also occur in dried fruit and when champagne ages in the bottle. Caramelization is an entirely different process from Maillard browning, though the results of the two processes are sometimes similar to the naked eye (and taste buds). Caramelization may sometimes cause browning in the same foods in which the Maillard reaction occurs, but the two processes are distinct. They are both promoted by heating, but the Maillard reaction involves amino acids, whereas caramelization is the pyrolysis of certain sugars. In the production of animal feed, the Maillard reaction can reduce feed quality by reducing the digestibility of amino acids. In making silage, excess heat causes the Maillard reaction to occur, which reduces the amount of energy and protein available to the animals that feed on it.
== Status == In the context of perpetual motion machines such as the Orbo, Professor Eric Ash has argued at the BBC: "Denying [conservation of energy] would undermine not just little bits of science - the whole edifice would be no more. All of the technology on which we built the modern world would lie in ruins". It is because of conservation of energy that "we know - without having to examine details of a particular device - that Orbo cannot work." Energy conservation has been a foundational physical principle for about two hundred years. From the point of view of modern general relativity, the lab environment can be well approximated by Minkowski spacetime, where energy is exactly conserved. The entire Earth can be well approximated by the Schwarzschild metric, where again energy is exactly conserved. Given all the experimental evidence, any new theory (such as quantum gravity), in order to be successful, will have to explain why energy has appeared to always be exactly conserved in terrestrial experiments. In some speculative theories, corrections to quantum mechanics are too small to be detected at anywhere near the current TeV level accessible through particle accelerators. Doubly special relativity models may argue for a breakdown in energy-momentum conservation for sufficiently energetic particles; such models are constrained by observations that cosmic rays appear to travel for billions of years without displaying anomalous non-conservation behavior.
Sources: en.wikipedia.org
On 19 June 2024, she received an honorary doctorate from the University of Cambridge in recognition of her achievements in chemistry. In 2024, she was inducted into the National Academy of Inventors. She has been awarded 13 honorary doctorates including the Weizmann Institute of Science, Aarhus University Denmark, University of Kent, the University of York, and the University of Bristol. On 10 August 2025, Robinson appeared on BBC Radio 4's Desert Island Discs.
=== Mechanism of action === Fomepizole is a competitive inhibitor of the enzyme alcohol dehydrogenase, found in the liver. This enzyme plays a key role in the metabolism of ethylene glycol, and of methanol.
== Treatment == Treating hypersomatotropism involves treating both the hypersomatotropism and the diabetes mellitus. Sometimes treatment is limited to the diabetes due to owners not wishing to treat the hypersomatotrism due to the associated costs. Monitoring of blood glucose levels is imperative as if improvement or resolution of insulin resistance is not identified hypoglycaemia can occur, leading to death. In dogs with progestogen induced hypersomatotropism the administration of progestogens should cease immediately. For cases derived from a mammary tumour it should be surgically removed.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.